Assessing medically unexplained symptoms: evaluation of a shortened version of the SOMS for use in primary care by Cristina Fabião et al.
Fabião et al. BMC Psychiatry 2010, 10:34
http://www.biomedcentral.com/1471-244X/10/34
Open AccessR E S E A R C H  A R T I C L EResearch articleAssessing medically unexplained symptoms: 
evaluation of a shortened version of the SOMS for 
use in primary care
Cristina Fabião*1, MC Silva2, António Barbosa3, Manuela Fleming4 and Winfried Rief5
Abstract
Background: To investigate the validity and stability of a Portuguese version for the Screening for Somatoform 
Symptoms-2 (SOMS-2) in primary care (PC) settings.
Methods: An adapted version of the SOMS-2 was filled in by persons attending a PC unit. All medically unexplained 
symptoms were further ascertained in a clinical interview and by contacting the patient's physicians and examining 
medical records, attaining a final clinical symptom evaluation (FCSE). An interview yielded the diagnosis of Clinical 
Somatization (CS) and the diagnosis of current depressive and anxiety disorders.
Results: From the eligible subjects, 167 agreed to participate and 34.1% of them were diagnosed with somatization. 
The correlation between the number of self-reported and FCSE symptoms was 0.63. After excluding symptoms with 
low frequency, low discriminative power and not correlated with the overall scale, 29 were retained in the final version. 
A cut-off of 4 symptoms gave a sensitivity of 86.0% and a specificity of 95.5% on the FCSE and 56.1% and 93.6% at self-
report. Stability in the number of symptoms after 6 months was good (k = 0.57).
Conclusions: The 29 symptoms version of the SOMS-2 with a cut-off of 4 showed a high specificity and sensitivity, 
being reliable as a referral tool for further specialized diagnosis.
Background
As the DSM (III-R and IV) Somatization Disorder was
extremely rare in PC settings, and many patients pre-
sented medically unexplained symptoms (MUS), the need
for an abridged somatization definition became evident.
The Somatic Symptom Index (SSI 6/4) [1] and the Multi-
somatoform Disorder (MSD) [2] were proposed and vali-
dated. Several studies reported high prevalence estimates
for Somatoform Disorders (SFD) in a PC context, not-
withstanding the problems raised by different criteria and
classification systems. Using ICD-10 criteria, values of
35.9% (current) and 39.4% (lifetime) were obtained [3];
with the DSM-IV criteria, 16.1% (current) [4] and 28.8%
[5]; 19.7% with the SSI 6/4 criteria [6] and 8% with other
abridged criteria [2,7].
Some researchers claim that screening for each symp-
tom requires a clinical analysis as a sound basis for
excluding organic disease or known "pathophysiological
mechanisms" [8-10]. Other studies do not support the
need for differentiation between explained and unex-
plained symptoms during the screening process [11,12].
Another dimension faced when screening Somatization
is the heterogeneity of its clinical forms [13] and the attri-
butional style [13]. The SOMS-2 [14,15] is a list of 53
physical complaints designed as a screener for SFD and
"resembles a questionnaire version of the criteria for SFD
according to the current classification systems" [16].
However an inconsistent recall of symptoms [17] has
made SFD diagnoses according to current classification
systems questionable. Evidence from GP evaluation and
medical records is relevant in addressing a further chal-
lenge for the ascertainment of SFD patients according to
current time criteria: the persistence over time of the ten-
dency to present several somatoform symptoms.
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for SFD in Portuguese. One used the ICD-10 Somatoform
Disorders Symptom Checklist [18]; the second used the
Questionnaire for physical manifestations of discomfort
(Questionário de Manifestações Físicas de Mal Estar
(QMFME)), based on the Psychosomatic Symptom
Checklist (SUNYA) (Attanasio et al, 1984) to assess
somatoform symptoms [19]. The QMFME included 19
items related to Nervous, Muscular, Digestive and Respi-
ratory Systems and showed a satisfactory internal consis-
tency within the four dimensions and as a whole.
However the validation study used a reduced list of symp-
toms, and it is possible that symptoms with good discrim-
inative power were left aside. The construct validity was
not verified against Depressive and Anxiety Disorders
and no attempt was made to validate criteria for clinical
diagnosis [20]. A third study [21] explored Portuguese
translations of the PILL (Pennebaker Inventory of Limbic
Languidness, 1982), an inventory with 54 items, and the
somatization subscale of the SCL-90-R. The last two
tools presented good psychometric properties but were
not validated against results of an interview and ask for
physical symptoms in general, not for medically unex-
plained ones. Again the validation did not explore speci-
ficity in relation to anxiety or depressive disorders.
The Somatoform Dissociation Questionnaire-20 (SDQ-
20) [22] was also validated in Portuguese. However it was
designed to measure somatoform dissociation and disso-
ciative disorders and not somatization in general.
This study was designed to validate the Portuguese ver-
sion of the SOMS-2 for use in PC settings. The perfor-
mance of the screening tool was also tested in the
presence of specific comorbidity patterns.
Methods
Subjects and data collection
A PC unit with eight general practitioners (GPs) who pro-
vide care for a population of about 11,000 inhabitants was
selected for this study. During a 10-day period alternating
mornings and afternoons (August-September, 2007) all
registered persons aged 18 years and older, able to read
Portuguese, with no dementia, acute psychosis or mental
retardation attending this unit were invited to participate.
All willing persons had to fill in a socio-demographic
questionnaire and the adapted Portuguese version of
SOMS-2 [23,24], helped whenever necessary by psychol-
ogy students. Within a short-time period participants
were interviewed at the PC unit by a psychiatrist (CF), to
ensure the somatoform nature of the symptoms reported
and standardization of the severity/disability criteria. At
the same time persons reporting no symptoms were again
asked about SOMS-2 symptoms using a randomized
order, for disclosure of false negatives at self-report. The
same interviewer conducted the Portuguese validated
version (5.0.0) of the MINI (1999, unpublished data dis-
played by Levy, P.). A trained assistant present at the
interview, selected participants that, throughout the
interview definitely did not accept medically unexplained
causes for their symptoms: they were labeled probable
"true somatizers" [13]. During a following two-month
period all symptoms for which a medical explanation was
in doubt were further discussed with the participant's GP.
The history of somatoform complaints was made for each
subject. As a standard procedure, medical records were
always consulted, as well as other sources of medical
information (if necessary) available on-line (hospital
inpatient and outpatient contacts). Data from post-sur-
gery diagnoses were obtained by contacting the surgeon
in charge. Based on all information collected a final con-
sensus about the symptom was reached (explained or
unexplained), yielding the Final Clinical Symptom Evalu-
ation (FCSE). Whenever information was insufficient for
a decision on a reported "borderline" symptom, it was
considered explained. Unexplained symptoms grafted
onto medical conditions were also admissible. Partici-
pants were considered to have a somatoform symptom at
FCSE even when they had an effective treatment for a
SFD, provided the diagnosis was made in the previous
two years.
After a period of six months stability of CS was tested
in a random sample of approximately 15% participants
who filled in the SOMS-2 and were interviewed by
another psychiatrist using the same procedure, blind to
first observation.
All participants received a description of the study and
signed written informed consent, according to the Code
of Medical Ethics of the World Medical Association Dec-
laration of Helsinki. The study was approved by the
Regional Primary Care Authority (Northern Region
Health Administration).
Measures
In the first section of the original SOMS-2 participants
are asked to report physical symptoms they have suffered,
either temporarily or continuously in the previous two
years, that significantly disturbed their well-being or their
personal lifestyle and for which doctors had not found a
clear cause. A list of 53 somatoform symptoms, 5 only for
women and 1 for men, are described. These are the phys-
ical symptoms listed for the diagnosis of SFD according
to DSM-IV-TR criteria and Somatoform Autonomic Dys-
function according to the ICD-10 criteria. The second
section has 15 questions to assess disability, the number
of consultations resulting from the symptoms, and inclu-
sion/exclusion criteria for all SFD. The original version
showed scores for sensitivity between 86% and 100% and
a 85% specificity for SFD according to DSM-IV criteria,
as well as a good test-retest reliability and correlation of
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of symptoms yielded by a structured interview [14]. In
this study an adapted Portuguese version of the SOMS-2
is used including a list of 46 symptoms, 45 for women and
42 for men [23]. The symptoms excluded because they
were seldom stated by primary care users (<5%) were: fre-
quent diarrhea, anal leakage, frequent bowel movements,
loss of tactile and pain sensation, blindness, seizures and
continuous or frequent vomiting during pregnancy.
Data collected from clinical interviews, GP longitudinal
assessment of the case and all data from medical records
were evaluated to form a diagnosis of Clinical Somatizers
(CS), taking into account the number of validated unex-
plained symptoms (usually 5 or more at FCSE) and result-
ing disability, recurrence and lifetime persistence and age
of onset (criteria available from the authors on request).
Seven out of the 8 GPs and the 2 psychiatrists who col-
lected and discussed the data had more than 20 years of
clinical experience. The CS diagnosis was the "gold stan-
dard" to estimate the discriminative power of each symp-
tom in the SOMS-2 list as well as its cut-off point.
Current depression and current anxiety disorders were
diagnosed using the MINI, a fully structured interview,
yielding 17 Axis I diagnoses according to DSM-III-R/IV
and ICD-10 criteria, whose validation studies yielded
good psychometric properties [25]. From the Portuguese
version (5.0.0), which generates DSM-IV diagnoses, ques-
tions for the following conditions were selected: major
depression with or without melancholic characteristics,
dysthymia, hypomania, mania, suicidal attempts history,
generalized anxiety disorder, simple phobia, social pho-
bia, agoraphobia with or without panic attacks, panic dis-
order, posttraumatic stress disorder, obsessive
compulsive disorder, substance abuse and dependence
disorders (alcohol, cannabis, etc).
Statistics
The overall prevalence and the prevalence ratio (PR) for
specific sample strata were calculated and the respective
95% confidence intervals are reported. For obtaining a
congruent overall inventory, the 46-symptoms adapted
SOMS-2 was validated using 3 cumulative criteria
applied to the FCSE. Only symptoms present in more
than 2.5% of participants, with good discriminative
power, that is, the 95% confidence interval for the positive
likelihood ratio (LR+) not including 1 (the symptom
should be more common in somatizers than in non-som-
atizers - sensibility/(1-specificity) and correlated with the
overall scale (r ≥ 0.20), were included in the final version.
The McNemar test or binomial distribution was used to
compare the "prevalence" of symptoms at self-report and
after clinical validation. The cut-off point for the SOMS-2
was studied using the ROC curve and the overall test
characteristics were calculated (sensitivity and specific-
ity) at self-report and after clinical validation, as well as
for specific sub-samples. The positive and negative pre-
dictive values were calculated assuming the prevalence of
somatization in the sample. The number of symptoms
reported was used to measure stability rather than the
specific symptoms reported. The statistic k was calcu-
lated for a series of two by two cross-tabulation according
to the number of symptoms reported at baseline and 6
months after (0, ≥1), (<2, ≥2), (<3, ≥3), ..., until (<8, ≥8).
The SPSS version 16 was used for statistical analyses and
a probability value of 0.05 was used as the limit for Type I
error (wrongly rejecting the null hypothesis).
Results
Of the 928 eligible subjects, 18% agreed to participate in
the whole evaluation (questionnaires and structured
interview). The response rate almost doubled for women
(20.5% vs. 13.0%) and declined gradually with age, from
28.0% for persons aged 18 to 44 years to 7.5% for those 65
or over. The age distribution of men or women in the
sample is not significantly different from that of persons
registered in the PC unit, though more women than
expected were enrolled (chi-square = 26.5, df = 1, p <
0.001). Actually participants were mainly women (74.3%)
and age ranged from 18 to 78 years, on average 43.7 (sd =
14.9), slightly higher for men (46.9 vs. 41.8 years). Most
participants were married (65.3%), 65.8% had 9 or more
years of full time education, 60.5% were employed and
62.3% lived in households inhabited by two or more gen-
erations (Table 1). The distribution of socio-demographic
characteristics was not significantly different among
somatizers and non-somatizers. The number of symp-
toms reported by participants on the SOMS-2 ranged
from 0 to 20; 37.1% yielded no symptoms, 25% of women
reported more than 4 symptoms and 25% of men more
than 3 symptoms.
The overall prevalence of CS was 34.1% (95%CI: 27.4-
41.6) and 10 participants with CS were probable "true"
somatizers. A current depressive disorder (CDD) was
present in 21.6% of participants, and 19,2% had major
depression, while a current anxiety disorder (CAD) was
present in 39 (23.4%) participants; they overlap in 18
(10.8%) participants and 110 (65.9%) were free from
depression and anxiety. Overall 48.5% of participants had
CS, anxiety or depressive disorders. In 33 participants
(19.8%) CS was comorbid with a depressive or anxiety
DSM-IV Disorder. Twenty-two cases (13.2%) of CS had
CDD and the same number had CAD. Twenty nine
(80.6%) persons with CDD also had CAD or CS. Twenty
nine (74.4%) persons with CAD also had at least one
CDD or CS and 33 (57.9%) with CS also had a current
depressive or anxiety disorder.
The prevalence of CS was higher in women than men
(PR = 1.63) and in those with 4-8 years of education com-
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Table 1: Sample characteristics and prevalence ratio for somatization
Characteristics Somatizers (n = 57) Non somatizers (n = 110) All (n = 167) Prevalence ratio 95% CI
Gender
Women 82.5 70.0 74.3 1.63 0.91-2.93
Men 17.5 30.0 25.7
Age (years)† 44.0 (12.4) 43.6 (16.0) 43.7 (14.9)
<45 47.4 53.6 51.5
≥45 52.6 46.4 48.5 1.18 0.77-1.80
Marital status
Single 14.0 21.8 19.2
Married 70.2 62.7 65.3 1.47 0.77-2.81
Divorced 14.0 10.9 12.0 1.60 0.72-3.58
Widowed 1.8 4.5 3.6 0.67 0.10-4.40
Years of full time education
<4 5.3 9.1 7.8 0.90 0.30-2.75
4-8 33.3 22.7 26.3 1.69 0.92-3.11
9-12 42.1 39.1 40.1 1.40 0.77-2.56
>12 19.3 29.1 25.7
Occupational status
Employed 66.7 57.3 60.5
Unemployed 17.5 14.5 15.6 1.02 0.59-1.77
Retired 14.0 19.1 17.4 0.73 0.39-1.39
Others 1.8 9.1 6.6 0.24 0.04-1.59
Household composition
Single 5.3 8.2 7.2
Couple 14.0 23.6 20.4 0.94 0.30-2.98
Couple with sons/
parents
70.2 58.2 62.3 1.54 0.56-4.22
Others 10.5 10.0 10.2 1.41 0.44-4.56
Income (minimum wage)‡
<1 8.9 10.2 9.8 1.06 0.43-2.60
1-3 73.2 67.6 69.5 1.22 0.69-2.17
>3 17.9 22.2 20.7
Comorbidity
Depression (current) 38.6 12.7 21.6 2.28 1.56-3.36
Anxiety (current) 38.6 15.5 23.4 2.06 1.39-3.06
Any current depression/
anxiety
57.9 21.8 34.1 2.65 1.75-4.03
Personality disorder 24.6 9.1 14.4 1.94 1.27-2.95
Hypochondria 6.0 3.0 4.0 1.53 0.67-3.53
Medicated psychoses 1.8 1.8 1.8
SOMS-2
No of symptoms§
women 5 [2-7] 1 [0-3] 2 [0-4]
men 2 [0-11] 0 [0-2] 1 [0-3]
Wellbeing affected¶ 83.0 50.0 64.8 2.65 1.39-5.06
ADL affected¶ 72.3 48.3 59.0 1.81 1.09-3.01
Prevalence ratio: prevalence in category indicated against category with no values shown; CI: confidence interval; †mean (standard deviation); ‡ 
for 164 participants; §median [1st and 3rd quartiles]; ¶for those reporting symptoms (n = 105) and prevalence ratio for (yes vs. no)
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in participants with any current depression/anxiety (PR =
2.65). The prevalence of CS is also higher in persons
reporting that symptoms affected their well being or
activities of daily living (Table 1).
The number of SOMS-2 symptoms emerging from the
final clinical symptom evaluation (FCSE) ranged from 0
to 18 and 44 (21.4%) participants yielded no symptoms.
The Spearman's rank correlation between the number of
self-reported and FCSE symptoms was 0.63, higher in
non somatizers (r = 0.58) than in somatizers (r = 0.42),
these having on average 3 more symptoms at the FCSE
(Figure 1).
Soms-2 validation
1. Frequency, discriminative power and internal consistency 
of symptoms
From the overall 46 symptoms evaluated at the FCSE in
the 167 participants, 17 were excluded from the final
inventory because they were stated by less than 2.5% of
participants (7, 9, 38, 39, F52 and M53). Symptoms 16, 17,
18, 19, 33, 42, 44, F48, F49 and F50 were also excluded,
since their discriminative power was low and symptom 3
was excluded since the correlation with the overall inven-
tory was low (Table 2). Two symptoms were only present
in somatizers, painful breathing and paralysis/weakness,
indicating a high discriminative power, followed by nau-
sea (30.8), difficulty in swallowing (28.9), bringing swal-
lowed food up again (27.1), vomiting (21.2), sexual
indifference (10.8), strong heart pounding (9.6), and
amnesia (9.6). Correlation with the global scale was low
for some "pain symptoms" (4, 5, 8) and high for strong
heart pounding (0.54), sexual indifference (0.48), bloating
or sweating (0.45) and burning sensations in chest or
stomach (0.43). Most symptoms were underreported by
participants, and 13 symptoms were more "prevalent" at
the FCSE than when self-reported (1, 2, 6, 10, 12, 13, 15,
24, 25, 28, 29, 36, 46). Considering the reduced list of 29
symptoms, R-SOMS-2, the Spearman's rank correlation
between self-report and FCSE was 0.63 for women and
0.67 for men, while the corresponding values for the 46
symptoms list was 0.62 both for men and women. The
internal consistency evaluated by Cronbach's alpha was
0.83 for both FCSE and SOMS-2 at self report, while for
the original 46 symptoms list the corresponding values
were 0.82 and 0.85.
2. Sensitivity and specificity (cut-off)
Figure 2 shows the "apparent" cut-off point of 4 symp-
toms in the SOMS-2 with 29 symptoms, calculated by the
ROC curve. Table 3 shows the sensitivity and specificity
for this cut-off on the 29 symptoms list as well as for the
full list. The ROC curve for the FCSE yielded the cut-offs
of 6 symptoms for women and 4 for men, but different
cut-off for self-report, 4 and 5, respectively. An overall
sensitivity of 86.0% and specificity of 95.5% was attained
both for SOMS-2 and R-SOMS-2 at FCSE, and the corre-
sponding values at self-report are 57.9% and 88.2% for the
former, decreasing slightly the sensitivity and increasing
the specificity for the R-SOMS-2 symptoms list, 56.1%
and 93.6%. The positive and negative predictive values
are PPV = 90.7% and NPV = 92.9% for FCSE and the cor-
responding values for the self-report are PPV = 71.7% and
NPV = 80.2% for the SOMS-2 and PPV = 82.1% and NPV
= 80.5% for the R-SOMS-2.
Considering the frequency of comorbid conditions in
the sample, CS with concomitant anxiety and/or depres-
sion, the test characteristics were also calculated consid-
ering four different groups: "pure" somatizers
(somatization without any depression/anxiety), somatiz-
ers with any depression or anxiety and corresponding
groups for non-somatizers (Figure 3). Sensitivity reaches
90.9% whenever somatizers have some depression and/or
anxiety, though attaining a lower value, 79.2%, in "pure"
somatizers. Specificity keeps an almost constant value of
95% for persons with some depression and/or anxiety or
for non somatizers free from any depression/anxiety. At
self-report it discloses only 33.3% of "pure somatizers"
increasing its sensitivity whenever somatizers have some
depression and/or anxiety (72.7%). The self-report R-
SOMS-2 performs equally well as FCSE for somatizers
without any depression or anxiety (95.3%).
3. Stability (intra-subject variation)
The correlation between the number of symptoms
reported at base-line on the full list of symptoms and
after a 6-month period for a sample of 24 persons was r =
0.67, increasing to 0.69 in the R-SOMS-2. Considering
the series of cut-off points from 1 to 8, the values of
agreement (k) were respectively 0.63, 0.50, 0.52, 0.33,
Figure 1 Scattergram of No. of symptoms self-reported and clini-
cally revised. (FCSE: final clinical symptom evaluation).
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SOMS-2 self reported SOMS-2 FCSE
Symptoms (%) Positive Likelihood )
ratio (95% CI)
(%) Positive Likelihood 
ratio (95% CI)
rpbi
1 Headaches 21.6 1.54 (0.8-2.7) 31.7 2.72 (1.7-4.2) 0.31
2 Pain in the stomach 6.6 2.30 (0.7-7.3) 18.6 4.70 (2.3-9.6) 0.37
4 Joint Pain 6.0 2.90 (0.8-9.8) 9.6 3.21 (1.2-8.4) 0.24
5 Pain in the legs and/or arms 11.4 2.65 (1.1-6.2) 12.0 2.36 (1.0-5.4) 0.21
6 Chest Pain 7.2 3.86 (1.2-12) 13.2 5.15 (2.1-12) 0.33
8 Pain during sexual intercourse 4.8 5.79 (1.2-28) 7.2 5.79 (1.6-20) 0.22
10 Nausea 5.4 2.41 (0.7-8.6) 10.2 30.80 (4.2-227) 0.23
11 Bloating 15.6 4.34 (2.0-9.4) 14.4 5.79 (2.4-14) 0.45
12 Discomfort in the area around the heart 5.4 6.75 (1.5-31) 10.2 6.27 (2.1-18) 0.36
13 Vomiting (pregnancy excluded) 3.0 5|57 7.2 21.20 (2.8-160) 0.32
14 Bringing swallowed food up again 5.4 15.40 (1.9-120) 9.0 27.10 (3.6-200) 0.37
15 Hiccough, or burning sensations in chest 
or stomach
6.6 5.15 (1.4-19) 12.0 5.79 (2.2-15) 0.43
22 Frequent urination 7.2 5.79 (1.6-20) 6.6 5.15 (1.4-18) 0.28
24 Strong heart pounding 8.4 11.58 (2.7-50) 18.0 9.65 (3.9-24) 0.54
25 Stomach discomfort or churning feeling 
in the stomach
13.8 2.51 (1.2-5.4) 23.4 3.86 (2.2-6.9) 0.39
26 Sweating (hot or cold) 12.0 4.50 (1.8-11) 14.4 7.33 (2.9-18) 0.45
27 Flushing or blushing 6.6 8.68 (1.9-39) 4.8 5.79 (1.2-27) 0.28
28 Breathlessness (without exertion) 3.6 9.65 (1.2-80) 11.4 7.24 (2.5-21) 0.33
29 Painful breathing or hyperventilation 2.4 5.79 (0.6-54) 6.0 10|57 0.38
30 Excessive tiredness or mild exertion 17.4 4.29 (2.1-8.8) 19.8 5.15 (2.5-10) 0.40
31 Blotchiness or discoloration of the skin 4.8 3.21 (0.8-13) 4.2 11.58 (1.4-93) 0.26
32 Sexual indifference (loss of libido) 7.8 23.20 (3.1-174) 10.8 15.43 (3.7-65) 0.48
34 Impaired coordination or balance 5.4 3.86 (1.0-15) 7.8 6.43 (1.8-22) 0.38
35 Paralysis or localized weakness 2.4 4|57 4.2 7|57 0.42
36 Difficulty swallowing or lump in the 
throat
6.0 17.4 (2.3-134) 9.6 28.95 (3.9-213) 0.39
37 Aphonia 6.0 4.50 (1.2-17) 7.2 5.79 (1.6-21) 0.25
41 Unpleasant numbness or tingling 
sensations
12.6 3.86 (1.7-9.0) 11.4 7.24 (2.5-21) 0.32
46 Amnesia (loss of memory) 10.2 3.54 (1.4-9.1) 14.4 9.65 (3.5-27) 0.40
47 Loss of consciousness 1.8 3|57 4.8 8|57 0.35
Excluded (no discriminative power in 
FCSE)
3 Back Pain 11.4 1.74 (0.7-4.0) 16.2 2.81 (1.4-5.6) 0.12
7 Pain in the anus 1.8 3.86 (0.4-41) 0.6 1|57 0.13
9 Pain during urination 1.2 2|57 1.2 2|57 0.23
16 Food intolerance 0.6 1|57 1.8 3.86 (0.4-41) 0.19
17 Loss of appetite 7.2 3.86 (1.2-12) 9.6 2.48 (0.9-6.3) 0.20
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values obtained were 0.55, 0.52, 0.52, 0.57, 0.48, 0.48, 0.43
and 0.50, respectively. Thus the cut-off of 4 symptoms has
the best agreement in terms of the number of symptoms
reported.
Discussion
Both the SOMS-2 and the 29 items reduced version, R-
SOMS-2, showed good characteristics in detecting CS,
though dependent on target population and the presence
of concomitant psychiatric diagnoses. As a screening tool
for primary care settings, the R-SOMS-2 with a cut-off of
four symptoms both at self-report and after clinical vali-
dation of symptoms reported, showed a high specificity
(93.6%) and satisfactory sensitivity (56.1%). Whenever
concomitant disorders such as anxiety and/or depression
are present the sensitivity increases (72.7%) and specific-
ity still keeps a high value (87.5%). Moreover the R-
SOMS-2 showed a relatively high stability in the number
of self-reported symptoms over a 6-month period (k =
0.57). According to the actual prevalence found in this
study (34.1%) it showed also high positive and negative
predictive values, 82.1% and 80.5%, respectively. On the
other hand the adapted SOMS-2 Portuguese version
showed both a high internal consistency (0.85) and a
slightly higher sensitivity (57.9%) at self-report. After
clinical validation sensitivity and specificity were equal
for the two SOMS-2 versions, 86.0% and 95.5%, respec-
tively.
It is possible that by strictly instructing the participants
to be aware of severity criteria, the common underesti-
mation of somatoform symptoms [10] has been rein-
forced in our study. Although stability of single symptoms
or disorders is not satisfactory [17,26], stability of somati-
zation seems to be less problematic when symptoms are
grouped into syndromes [26,27]. Correlation between
self-reported symptoms and symptoms assessed by doc-
tors (with regard to the previous two years) was 0.63,
lower than the 0.75 reported by Rief and colleagues [18].
The R-SOMS-2 includes not just the most frequent
symptoms in PC, but rather those more frequently posi-
tive among somatizers in comparison to non-somatizers,
18 Bad taste in mouth, or excessive coated 
tongue
6.6 3.38 (1.0-11) 4.2 4.82 (0.9-24) 0.16
19 Dry mouth 11.4 2.65 (1.1-6.2) 7.2 1.38 (0.5-4.2) 0.05
33 Unpleasant sensations in or around the 
genitals
1.8 3.86 (0.4-42) 3.6 3.86 (0.7-20) 0.16
38 Urinary retention 0.0 0.0
39 Hallucinations 1.8 3|57 1.2 2|57 0.10
42 Double vision 3.0 1.29 (0.2-7.5) 3.6 3.86 (0.7-20) 0.20
44 Deafness 1.8 3|57 2.4 5.79 (0.6-54) 0.08
F48 Painful menstruation 8.1 1.09 (0.3-3.7) 12.1 1.43 (0.6-3.7) 0.33
F49 Irregular menstruation 2.4 0.82 (0.1-8.8) 3.2 0.55 (0.1-5.1) 0.18
F50 Excessive menstrual bleeding 4.0 2.46 (0.4-14) 8.1 2.46 (0.7-8.3) 0.27
F52 Unusual or copious vaginal discharge 0.0 0.0
M53 Erectile or ejaculatory dysfunction 2.3 1|10 2.3 1|10 0.15
CI: confidence interval; rpbi: point-biserial correlation coefficient with the overall sum of symptoms; F48 to F52: symptoms only for women; M53: 
symptom only for men; for these groups of symptoms frequencies, positive likelihood and correlations were calculated for the respective groups 
(124 women and 43 men); whenever the Positive Likelihood ratio [sensibility/(1-specificity)] was not defined the number of somatizers with that 
symptom is indicated (sensibility) since non-somatizers did not have the symptom (specificity = 1)
Table 2: Frequency of SOMS-2 symptoms (%), discriminative power (LR+) and correlation with SOMS-2 full scale 
Figure 2 No. of symptoms (out of 29) in women and men showing 
the "natural" 4 symptoms cut-off point.
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able high correlation with the total scale. It may seem
unreasonable excluding symptoms with relatively high
frequency, such as "dry mouth" or "painful menstruation",
but they are not "characteristic" of CS, they are as well
important in other patients, therefore not adequate for
discriminating CS. On the other hand a quite frequent
symptom like "back pain" was also excluded because the
correlation with the overall scale was low, meaning that
its pattern of variation did not follow the overall scale
pattern. The three cumulative criteria for including
symptoms in this revised version resulted in a shorter
scale with properties similar to the SOMS-2, therefore
better suited to PC settings.
The ROC curve analysis for the FCSE yielded the same
cut-off of the SSI (4 symptoms for men and 6 symptoms
for women) reported by Escobar and colleagues [1],
although the SOMS-2 asks for symptoms occurring only
during the previous two years and not for lifetime symp-
toms. The cut-off of 4 symptoms is near the proposed 3
symptoms for Multisomatoform Disorder (MSD) [2],
given these are current symptoms. At self-report, the R-
SOMS-2 displayed seven false-positive cases and FCSE
five. At interview those subjects stated that symptoms did
not interfere at all with daily routines, this way loosing
the severity threshold and becoming "negatives" when
facing the interviewer. Using R-SOMS-2, we found 25
false-negatives, at self-report, seven of them overlapping
with the 8 false-negatives at FCSE. Most of those 25 false-
negatives used a medical disease they actually had as a
kind of umbrella for other (unexplained) symptoms. At
FCSE those symptoms turned to unexplained. As
reported for false-positives, the clinical interview setting
also seemed to interfere in the opposite way, leading
some participants to enhance their complaints. This
problem seems to be not exclusively explained by the rel-
ative instability of the individual system of causal attribu-
tions, since the observer presence affects the degree of
severity of the complaints reported. Ten cases were con-
sidered probable "true" somatizers within the CS group,
and among the false-negatives there were six cases con-
sidered as probable "true" somatizers. We think these
patients will seldom screen positive using self-report
measures of somatoform disorders or symptoms, since
they need a thorough investigation involving their doc-
tors in order to decide the nature of symptoms. This
group of somatizers blurs the distinction between MUS
and medically explained symptoms (MES). Along with
the fact that MUS frequently prolong or are grafted on
physical symptoms, they can add an explanation for the
non relevance in distinguishing between MUS and MES
when screening somatoform symptoms or disorders
using self-report measures, as advocated by some authors
[12,28]. In spite of that, the R-SOMS-2 presents a satis-
factory sensitivity and good specificity for moderate som-
atization, being an adequate screening tool for referring
primary care users for further specialized diagnosis. It is
now possible to use in the PC Portuguese settings the
adapted SOMS-2 as a checklist of DSM-IV and ICD-10
Table 3: Test characteristics (%) and predictive values (%) at self-report and FCSE
SOMS-2 FCSE SOMS-2 self-report
Cut-off points/No symptoms Sensitivity Specificity PPV NPV Sensitivity Specificity PPV NPV
Women (≥6/45) 87.2 98.7 97.6 92.7 (≥4) 61.7 87.0 74.4 78.8
Men (≥4/42) 80.0 87.9 66.7 93.5 (≥5) 40.0 90.9 57.1 83.8
All 86.0 95.5 90.7 92.9 57.9 88.2 71.7 80.2
Women (≥4/29) 89.4 94.8 91.3 93.6 59.6 94.8 87.5 79.3
Men (≥4/29) 70.0 97.0 87.5 91.4 40.0 90.9 57.1 83.3
All 86.0 95.5 90.7 92.9 56.1 93.6 82.1 80.5
FCSE: Final Clinical Symptoms Evaluation; PPV: positive predictive value; NPV: negative predictive value
Figure 3 Test characteristics (4 symptoms cut-off point) for differ-
ent comorbidity patterns. (somatizers, n = 24; somatizers with any 
depression/anxiety, n = 33; non-somatizers with any depression/anxi-
ety, n = 24; free of psychopathology, n = 86).
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screener of possible cases. R-SOMS-2 is longer than two
other screeners assessed in PC settings: the PHQ-15
(Patient Health Questionnaire) with 15 physical
(explained or unexplained) symptoms [28], and the Oth-
mer and DeSouza test with seven symptoms [16]. The
first is considered to be a measure of severity of physical
symptoms not yielding scores of self-report unexplained
symptoms. The second, in a Spanish validation study,
assessing its validity as a screener for Somatization Disor-
der [29] disclosed values of sensibility and specificity near
those we obtained for moderate somatization (CS) with a
cut-off of 4 symptoms: 88% and 78%, respectively, for a 3
symptom threshold.
The estimated prevalence of CS found in this study,
34.1%, is higher than the 14.0% for MSD, in Spanish PC
units [5] and the median prevalence of 16.6% for the
abridged SSI 4,6 criteria in a systematic review [30]. On
one hand these studies used a more restrictive criteria,
the SSI (4,6) and on the other hand women were over-
represented in the sample used in our study. Nevertheless
all PC users within the study period were invited to col-
laborate, irrespective of the motive why they came to the
health centre, that may have been preventive procedures
involving medical or nursing care (vaccinations, family
planning a pregnancy routine checks) or consultations.
This way it might be expected that persons were freer of
mental distress, so the prevalence obtained is high, par-
ticularly when comparing with the Spanish study [5].
Another possible explanation being the fact that MSD is a
current diagnosis and CS was considered during the pre-
vious two years. Indeed the prevalence of CS was higher
in women as well as in participants with 4-8 years of for-
mal education and presenting anxiety and depressive dis-
orders. Another study in the southern Portugal disclosed
a prevalence for DSM-IV Major Depression (as assessed
by interview) of 13% [31] but only patients between 35-65
years with an appointment with their doctor were eligi-
ble. The more restrictive inclusion criteria (patients wait-
ing for an appointment with the doctor) were expected to
display a higher prevalence of depression as compared to
the 19.2% found in this study. Gusmão et al [32] in a
review article reported a prevalence of 31.6% for depres-
sion (12% for clinical and 19.6% for sub-threshold depres-
sion) in a study carried out twenty years ago, during
which 927 consecutive participants from Portuguese PC
centres were interviewed [31]. A recent European study
[33] displayed a prevalence for Major Depression in Por-
tugal of 17.8% for women and 6.5% for men. In the same
setting, we found 21.8% and 11.6%, respectively. Portu-
guese research on SFD and syndromes is lacking but we
may conclude that there is a relative homogeneity in the
prevalence of mental disorders in PC all over the country,
specially for Major Depression.
The low response rate (18%) is a relevant limitation of
the study, since the sample size is reduced and may not be
representative of the PC population. Nevertheless the age
distribution of participants was not significantly different
from that of registered persons, but the over-representa-
tion of women may be responsible for the high prevalence
found. Finally, we are aware that this validation study
would have more strength if other PC units all over the
country had been involved.
Conclusion
The 29 items reduced version of the SOMS-2 showed to
be a valid tool for detecting CS in primary care settings,
specially whenever concomitant disorders such as anxiety
and/or depression are present. Thus the R-SOMS-2 is a
reliable referral tool for further specialized diagnosis.
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